QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 9/4/393    most recent 15228517-2007-019v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Krauze, M. T. Articles by Bankiewicz, K. S. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts

Department of Neurological Surgery, Brain Tumor Research Center (M.T.K., T.K., Y.Y., J.F., K.S.B.), and Division of Hematology-Oncology (C.O.N., E.K., J.W.P.), University of California, San Francisco, San Francisco, CA; Hermes Biosciences, Inc., South San Francisco, CA (C.O.N., D.D., D.B.K.); USA

Address correspondence to Krystof S. Bankiewicz, Department of Neurological Surgery, MCB226, University of California, San Francisco, 1855 Folsom St., Mission Center Building, San Francisco, CA 94103-0555, USA (krystof.bankiewicz{at}ucsf.edu).

We have previously shown that convection-enhanced delivery (CED) of highly stable nanoparticle/liposome agents encapsulating chemotherapeutic drugs is effective against intracranial rodent brain tumor xenografts. In this study, we have evaluated the combination of a newly developed nanoparticle/liposome containing the topoisomerase I inhibitor CPT-11 (nanoliposomal CPT-11 [nLs-CPT-11]), and PEGylated liposomal doxorubicin (Doxil) containing the topoisomerase II inhibitor doxorubicin. Both drugs were detectable in the CNS for more than 36 days after a single CED application. Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil. The combination of the two agents produced synergistic cytotoxicity in vitro. In vivo in U251MG and U87MG intracranial rodent xenograft models, CED of the combination was also more efficacious than either agent used singly. Analysis of the parameters involved in this approach indicated that tissue pharmacokinetics, tumor microanatomy, and biochemical interactions of the drugs all contributed to the therapeutic efficacy observed. These findings have implications for further clinical applications of CED-based treatment of brain tumors.

Key Words: brain tumor • CED • CPT-11 • Doxil • irinotecan • liposome • xenograft

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Inoue, Y. Yamashita, M. Nishihara, S. Sugiyama, Y. Sonoda, T. Kumabe, M. Yokoyama, and T. Tominaga Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models Neuro-oncol, January 1, 2009; 11(2): 151 - 157. [Abstract] [Full Text] [PDF]